Hepatitis C: New Therapies in

Hepatitis C: New Therapies in 216-217 Mark Sulkowski, MD Professor of Medicine Johns Hopkins University School of Medicine Medical Director, Viral Hepatitis Center Divisions of Infectious Diseases and Gastroenterology/Hepatology Baltimore, Maryland

Current HCV direct acting antiviral regimens cure the majority of persons treated in phase 3 trials Receptor binding and endocytosis Highly efficacious DAAs target different points in the HCV lifecycle 1 Transport and release New England Journal of Medicine trials in GT 1 published in 214 2 96% Fusion and uncoating Virion assembly Translation and polyprotein processing (+) RNA ER lumen NS3 protease inhibitors Membranous web LD LD ER lumen LD NS5A inhibitors RNA replication Nucleos(t)ide and Nonnucleoside NS5B inhibitors 368/ 3826 Sustained Virologic Response [SVR] 1. Lindenbach BD, Rice CM. Nature 25;436(Suppl):933 8; 2. Liang J, Ghany MG. N Engl J Med 214;37:243 7; 3. Burki T. Lancet Infect Dis 214;14:452 3

New HCV DAAs where is the unmet medical need? Access to effective HCV treatment Regional registration of novel DAAs HCV treatment without the need for baseline assessment of genotype and/or RAVs Pangenotypic High barrier to emergence of resistant variants Shorter therapy Reduce cost Increase treatment capacity Curative treatments for persons who fail first course regimens

HCV treatment regimens available in 216 217 Antiviral NS3 NS5A Nuc Non- NS5B Nuc NS5B RBV IFN Narlaprevir (216) Paritaprevir/ritonavir/Ombitasvir + Dasabuvir Asunaprevir/Daclatasvir/Beclabuvir 1a only Grazoprevir/Elbasvir FDC (216) ABT493/ABT53 (217) Sofosbuvir/Ledipasvir FDC Sofosbuvir/Velpatasvir FDC (216) Sofosbuvir + Daclatasvir Sofosbuvir + Simeprevir MK3682/MK848/Grazoprevir FDC (218) Sofosbuvir/Ledipasvir/GS9857 FDC (217)

Novel DAAs [Registration pathway outside of the Food and Drug Administration and European Medicines Agency]

Phase III PIONEER Study: Narlaprevir + PegIFN/RBV International multicenter randomized placebo-controlled doubleblind study 42 non-cirrhotic naïve and treatment-experienced patients with GT1 12 weeks of Narlaprevir 2 mg QD + Ritonavir mg QD + PR + 12 weeks of PR Randomization 2:1 to Narlaprevir/Ritonavir and placebo (28 patients on Narlaprevir) 27 Naives Narlaprevir/r + PegIFN/RBV PegIFN/RBV + Placebo PegIFN/RBV PegIFN/RBV Follow-up Follow-up 15 PegIFN/RBV failurers Narlaprevir/r + PegIFN/RBV PegIFN/RBV + Placebo PegIFN/RBV PegIFN/RBV Follow-up Follow-up Weeks 4 12 24 36 48 6 72 Unblinding Interim analysis SVR 24 In active-treatment group SVR 24 In placebo group 6

Patients Phase III PIONEER Study SVR24 by Fibrosis Stage Narlaprevir/r + PegIFN/RBV % 9% 8% 7% 85,6% 88,2% All Treatment-naive Previously treated 95,% 91,9% 87,2% 82,5% 78,8% 75,% 71,6% 65,7% 66,7% 6% 5% 53,3% 4% 3% 2% 1% % 77/9 82/93 52/63 23/35 57/62 57/6 34/39 15/2 2/28 26/33 16/24 8/15 F F1 F2 F3 F F1 F2 F3 F F1 F2 F3 LOD = LLOQ <15 IU/mL 7

Phase III PIONEER Study: Safety Data Adverse events, % (n) Narlaprevir/r + PegIFN/RBV N=282 Placebo + PegIFN/RBV N=138 Most common adverse events list (>1% of cases) Neutropenia 47,5% (134) 54,4% (75) Leukopenia 35,5% () 39,9% (55) Influenza-like illness 29,1% (82) 31,9% (44) Asthenia 27,3% (77) 26,1% (36) Hemoglobin decrease 24,1% (68) 23,2% (32) Pyrexia 23,4% (66) 21,7% (3) Anaemia 22,7% (64) 22,5% (31) Thrombocytopenia 19,5% (55) 22,5% (31) Weight decrease 16,31% (46) 2,3% (28) Alopecia 15,25% (43) 8,7% (12) Headache 12,8% (36) 11,6% (16) Cough 8,9% (25) 12,3% (17)

NS5A Inhibitor + NS3 Protease Inhibitor [ nuke sparing ]

Grazoprevir Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial Ann Intern Med. 215;163(1):1-13. doi:1.7326/m15-785

Grazoprevir/Elbasvir: Impact of baseline NS5A RAVs in patients with HCV 1a and 1b infection GT1a-infected EBR/GZR 12 Weeks (No RBV): Lower SVR with key RAVS Population sequencing is adequate for clinical interpretation [no need for deep sequencing] RAV Position SVR12 Patients with RAVs (NGS 1% ST) SVR12 Patients with RAVs (PopSeq) 28 61/68 (89.7%) 29/33 (87.9%) 3 14/23 (6.9%) 4/1 (4.%) 31 15/23 (65.2%) 5/13 (38.5%) 93 9/14 (64.3%) 5/8 (62.5%) GT1b-infected EBR/GZR 12 Weeks (No RBV): No impact of RAVS RAV Position SVR12 Patients with RAVs (PopSeq) 28 4/4 (.%) 3 16/16 (.%) 31 17/19 (89.5%) 93 21/22 (95.5%) Jacobson I, et al. 66th AASLD; San Francisco, CA; November 13-17, 215; Abst. LB-22.

Prevalence GZV/EBR: longer treatment (16 weeks) and addition of RBV lead to high SVR rate in patients with baseline NS5A RAVs (positions 28, 3, 31 and 93) Efficacy of EBR/GZR 16/18 Weeks (+ RBV) in GT1a PR Non-responders with Baseline NS5A RAVs Population Sequencing EBR RAVs NS5A Class RAVs Next-Generation Sequencing at 1% ST EBR RAVs NS5A Class RAVs No RAVs: 51/52 (98%) No RAVs: 44/52 (85%) No RAVs: 48/52 (92%) No RAVs: 38/52 (73%) 51 51 1 1 44 44 8 8 48 48 4 4 38 38 14 14 Jacobson I, et al. 66th AASLD; San Francisco, CA; November 13-17, 215; Abst. LB-22.

C-SURFER: Grazoprevir/Elbasvir in patients with Stage 4 or 5 Chronic Kidney Disease Treatment Wk 12 Follow-up Wk 4 Follow-up Wk 16 Randomized period SVR12* GT1 HCV-infected pts with stage 4/5 CKD (n = 224) Grazoprevir/Elbasvir (n = 111) Placebo (n = 113) Open-label period Grazoprevir/Elbasvir (n = 113) 99% 98% Grazoprevir/elbasvir dosed orally mg/5 mg once daily 76% on dialysis 55% with diabetes 52% GT1a, 48% GT1b 6% cirrhosis Roth D, et al. Lancet. 215;386:1537-1545. *Modified full analysis set population (mfas).

SURVEYOR-I and -II: High SVR in non-cirrhotic patients with ABT-493 + ABT-53 for 8 weeks in G1/2 and 12 weeks in G4/5/6 SVR12 (%) Study design SVR12 following ABT-493 + ABT-53 for 8 weeks (G1/2) or 12 weeks (G4/5/6) SURVEYOR-I G1 non-cirrhotic TN or P/R exp SURVEYOR-II G2 non-cirrhotic TN or P/R exp SURVEYOR-I (part 2) G4/5/6 non-cirrhotic TN or P/R exp ABT-493 (3 mg) + ABT-53 (12 mg) ABT-493 (3 mg) + ABT-53 (12 mg) ABT-493 (3 mg) + ABT-53 (12 mg) SVR12 SVR12 Week 8 12 2 24 8 6 4 2 97 98 33/34 53/54 22/22 1/1 11/11 G1 G2 G4 G5 G6 8 weeks (ITT) 12 weeks Gane E, et al. EASL 216, Barcelona. #SAT-137; Poordad F, et al. EASL 216, Barcelona. #SAT-157

Patients (%) High SVR rates with ABT-493 + ABT-53 for 8 weeks (non-cirrhotic) and 12 weeks (cirrhotic) in patients with GT3 infection Muir et al. 29 patients without cirrhosis treated with ABT493 + ABT53 for 8 weeks (no RBV) No virologic failure No SAE or DC due to AE Kwo et al. 48 patients with cirrhosis and no prior treatment 12 weeks ABT 493 + 53 ± RBV No virologic failure No impact of baseline RAVs including Y93H/N No benefit observed with RBV 5 Muir et al: SVR12 97 1 patient withdrew consent after TW6: UND HCV RNA at time of d/c 28/29 28/28 SVR12 Kwo et al: SVR12 mitt SVR12 Muir A, et al. EASL 216, Barcelona. PS98

SVR12 (% pts) n=6 n=22 n=22 MAGELLAN-1 Study: ABT-493 and ABT-53 in non-cirrhotic, GT1 infected patients who have failed DAA-containing regimens ABT-493 ABT-53 ABT-493 ABT-53 RBV ABT-493 ABT-53 2 mg 8 mg 3 mg 12 mg 8 mg 3 mg 12 mg Arm stopped early, inadequate results of dose-finding studies in pts across all genotypes Day Wk 12 Wk 24 Wk 36 SVR12 15/16 (94%) 1a; 3D+RBV failure Breakthrough NS3:Y 56H, D168A/T NS5A:M28V, Q3L/R [CATEGO RY NAME] [CATEGO RY NAME] SVR12 9/1 (9%) 1a; DCV, TVR, PR failure Relapse; NS5A: L31M, H58D [CATEGO RY NAME] SVR12 SVR12 6/6 (%) [CATEGO RY NAME] SVR12 15/15 (%) % SVR12 in 1 pts with Y93 NS5A RAVs % SVR12 in 26 pts w/ Q8 or R155 NS3 RAVs % SVR12 in 17 pts w/ prior failure of a SOFcontaining regimen 9 8 7 6 5 4 3 2 1 91 86 6/6 2/ 22 ITT 19/ 22 6/6 95 2/ 21 mitt 95 19/ 2 BT 1 1 Relapse 1 1 LTFU 1 2 -- -- -- Poordad F, et al. EASL 216, Barcelona. #GS11

NS5A inhibitor + NS5B Nucleotide Analogue Polymerase inhibitor

HCV suppression by nucleos(t)ide analogue NS5B polymerase inhibitors Sofosbuvir, β-d-2'-deoxy-2'-α-fluoro-2'-β-cmethyluridine nucleotide prodrug (21) Potent HCV suppression with sofosbuvir alone, with ribavirin or with both interferon/ribavirin (21) Sofia J Med Chem 21 Gane NEJM 213 HCV Drug Development Advisory Group

SVR12 (%) ASTRAL-1, 2, and 3: Sofosbuvir/Velpatasvir (SOF/VEL) FDC for 12 weeks SVR12 by Genotype 98 98 99 95 97 8 6 4 2 relapse 2 LTFU 1 WC 1 LTFU 11 relapse 2 others 1 death 2 115 135 323 328 237 238 264 277 116 116 Total GT1 GT2 GT3 GT4 GT5 GT6 34 35 41 41 Jacobson IM. HEPDART 215

ASTRAL-4: SOF/VEL in patients with CTP B cirrhosis n=9 n=87 n=9 Wk Wk 12 Wk 24 Wk 36 SOF/VEL SOF/VEL + RBV SOF/VEL SVR12 SVR12 SVR12 267 treatment-naive or - experienced G1 6 with Child B cirrhosis 55% treatment-experienced MELD <15 = 95% Ascites 75 83%; encephalopathy 58 66% 8 6 4 2 SOF/VEL 12 wk SOF/VEL+RBV 12 wk 94 83 88 96 85 86 92 5 5 75/ 9 82/ 87 77/ 9 6/ 68 65/ 68 65/ 71 Overall G1 G3 G2, 4, and 6 7/ 14 11/ 13 6/ 12 86 G2 3/4 G2 4/4 G2 4/4 G4 2/2 G4 4/4 G4 2/2 G6 1/1 Breakthrough, n - 1 1 - - - - 1 1 - - - Relapse, n 11 2 7 5 1 3 6 1 4 - - - LTFU, n 1-3 1-3 - - - - - - Death, n 3 2 2 2 2-1 - 1 - - 1 Charlton MR, et al. AASLD 215, San Francisco. #LB-13

Resistance analysis in 1284 patients with G1 6 HCV infection treated with SOF/VEL in the ASTRAL 1-4 studies Overall prevalence of RAVs: NS5A: 36% Only Y93 variants considered NS5A specific RAV for velpatasvir ASTRAL 1 3 SVR12 (%) 8 6 No RAVs RAVs 99 98 97 97 89 (1% cutoff) SVR12 in ASTRAL-4 (G1 4) SOF/VEL NS5A RAVs - +RBV* 58/6 (97%) NS5A RAVs + 24/25 (96%) 4 2 637/ 643 Overall G1 G2 G3 G4 6 VF: 13 373/ 38 251/ 251 2 73/ 75 Both G1a 7/ 7 162/ 162 224/ 23 1 39/ 44 91/ 91 / Baseline: Q3±L31: n=2 Post-VF: Y93: n=2 Baseline: A3K, n=1 Y93, n=4 None, n=5 Post-VF: Y93, n=1 Hezode C, et al. EASL 216, Barcelona. #THU-216

Sofosbuvir/Velpatasvir and Placebo Adverse events occurring in >5% of patients Patients, n (%) SOF/VEL 12 wk n=135 Placebo 12 Week (N = 116) Headache 296 (29) 33 (28) Fatigue 217 (21) 23 (2) Nausea 135 (13) 13 (11) Insomnia 87 (8) 11 (1) Nasopharyngitis 121 (12) 12 (1) Diarrhoea 73 (7) 8 (7) Cough 57 (6) 4 (3) Irritability 49 (5) 4 (3) Arthralgia 56 (5) 9 (8) Back pain 56 (5) 11 (1) Asthenia 58 (6) 9 (8) Jacobson IM. HEPDART 215

NS5A inhibitor + NS3 Protease Inhibitor + NS5B Nucleotide Analogue Polymerase inhibitor

SOF/VEL + Voxilaprevir (VOX,GS-9857) for 12 weeks in treatment-experienced (including DAAs) patients with HCV GT1-6 SVR12 (%) Baseline Characteristic VEL/SOF + GS-9857 Cirrhosis, n (%) 61 (48) Mean HCV RNA, log 1 IU/mL (range) HCV genotype, n (%) 6.3 (3.8 8.1) 1 63 (49) 2 21 (16) 3 35 (27) 4/6 9 (7) DAA experience, n (%) None (G2 6 only) 27 (21) 1 DAA class 36 (28) 2 DAA classes 65 (51) Lawitz E, et al. EASL 216, Barcelona. #PS8 8 6 4 2 SVR12 (overall and by genotype) 99 97 127/ 128 63/63 21/21 34/35 9/9 Overall G1 G2 G3 G4/6 1 pt relapsed at post-treatment Wk 8 128 patients enrolled

SOF/VEL + VOX for 12 weeks in treatment-experienced G1 6 pts, including those previously treated with DAAs 98 99 97 8 6 4 67/67 6/61 92/93 35/35 27/27 35/36 65/65 2 Resistance analysis No Yes Cirrhosis No Yes Prior NS5A experience * 1 2 No. of DAA classes *G2 6 pts who failed PR SVR12 (%) by subgroup Lawitz E, et al. EASL 216, Barcelona. #PS8

SOF/VEL + VOX for 6 or 8 weeks in treatment-naïve, HCV GT 1-6 infected patients ± cirrhosis SVR12 (%) Two Phase 2 studies of 6 or 8 weeks of SOF/VEL (4/ mg) + GS-9857 ( mg) QD G1 6 (pangenotypic) Treatment naive US and New Zealand G1 6 n=166 G1 n=31 SOF/VEL FDC + GS-9857 SOF/VEL FDC + GS-9857 SOF/VEL FDC + GS-9857 + RBV SVR12 SVR12 SVR12 Week 6 8 18 2 Baseline characteristics SOF/VEL + GS-9857 6-week n=67 SOF/VEL + GS-9857 8-week n=99 SOF/VEL + GS-9857 + RBV 8-week n=31 Mean age, y (range) 53 (18 72) 55 (19 76) 59 (43 71) Male, n (%) 35 (52) 61 (62) 19 (61) White, n (%) 58 (87) 81 (82) 26 (84) Mean BMI, kg/m 2 (range) 26 (18 42) 29 (19 47) 29 (19 52) IL28B CC, n (%) 23 (34) 27 (27) 12 (39) Cirrhosis, n (%) 63 (64) 31 () Mean HCV RNA, log 1 IU/mL (range) 6.2 (3.6 7.6) 6.1 (4.7 7.4) 6.3 (5.4 7.3) G1, n (%) 35 (52) 69 (7) 31 () G2, n (%) 6 (9) 6 (6) G3, n (%) 21 (31) 18 (18) G4, n (%) 5 (7) 5 (5) G5, n (%) G6, n (%) 1 (1) Gane E, et al. EASL 216, Barcelona. #SAT-138 8 6 4 2 HCV G1 SVR12 by cirrhosis status 71 SOF/VEL + GS-9857 6 week No cirrhosis 94 SOF/VEL + GS-9857 8 week SOF/VEL + GS-9857 8 week Cirrhosis 81 25/35 36/36 31/33 25/31 SOF/VEL + GS-9857 + RBV 8 week

SVR12 (%) SVR12 (%) Short-duration treatment with SOF/VEL + VOX in treatmentnaive G1-6 HCV-infected patients with or without cirrhosis 8 6 4 2 HCV G2-6 SVR12 by genotype and cirrhosis status (all failures were HCV relapse No cirrhosis 88 67 6 28/32 4/6 21/21 3/5 Overall G2 G3 G4 SOF/VEL + GS-9857 6 weeks Cirrhosis 93 94 83 8 6 4 2 28/3 6/6 17/18 5/6 Overall G2 G3 G4,6 SOF/VEL + GS-9857 8 weeks Phase III, global clinical trials are ongoing (POLARIS Studies) SOF/VEL/VOX FDC for 8 Weeks compared to SOF/VEL FDC for 12 Weeks in DAA-naïve patients SOF/VEL/VOX FDC for 12 Weeks in DAA-experienced patients SOF/VEL/VOX FDC for 12 weeks or SOF/VEL FDC for 12 weeks DAA-experienced patients without prior treatment with a NS5A inhibitor SOF/VEL/VOX FDC for 8 Weeks or SOF/VEL for 12 Weeks for patients with HCV GT 3 and cirrhosis Gane E, et al. EASL 216, Barcelona. #SAT-138

SVR24 (%) Phase 2 C-CREST 1 and 2: GZR/MK-848/MK-3682 (novel nucleotide NS5B inhibitor) for 8 weeks in non-cirrhotic patients with in HCV GT 1, 2 and 3 9 8 7 6 5 4 3 2 1 23/ 23 23/ 23 87 69 SVR12=91% (21/23) 1 late LTFU had achieved SVR12 24/ 24 2/ 23 11/ 16 MK-3682 (3 mg)/gzr/ebr MK-3682 (45 mg)/gzr/ebr MK-3682 (3 mg)/gzr/mk-848 MK-3682 (45 mg)/gzr/mk-848 6 9/ 15 71 1/ 14 Gane E, et al. EASL 216, Barcelona. #SAT-139 94 86 86 SVR12=9% (19/21) 1 late LTFU had achieved SVR12 15/ 16 18/ 21 19/ 22 G1 G2 G3 95 2/ 21 91 2/ 22

New HCV DAAs where is the unmet medical need? Access to effective HCV treatment Narlaprevir DAAs registered regionally (e.g., Ravidasvir in Egypt) HCV treatment without the need for baseline assessment of genotype and/or RAVs + Pangenotypic + Shorter therapy + Curative treatments for persons who fail first course regimens SOF/VEL with or without VOX ABT-493 + ABT53 Grazoprevir + MK848 + MK3682